MA31252B1 - Macrolides a base d'erythromycine - Google Patents

Macrolides a base d'erythromycine

Info

Publication number
MA31252B1
MA31252B1 MA32219A MA32219A MA31252B1 MA 31252 B1 MA31252 B1 MA 31252B1 MA 32219 A MA32219 A MA 32219A MA 32219 A MA32219 A MA 32219A MA 31252 B1 MA31252 B1 MA 31252B1
Authority
MA
Morocco
Prior art keywords
erythromycin
macrolides
based macrolides
compounds
formula
Prior art date
Application number
MA32219A
Other languages
Arabic (ar)
English (en)
Inventor
Sr Richard Allen Buzon
Mark Edward Flanagan
Zhengong Bryan Li
Thomas Victor Magee
Mark Carl Noe
Usa Datta Reilly
Daniel William Widlicka
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA31252B1 publication Critical patent/MA31252B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (i), r1, r2, et x étant tels que définis ici. La présente invention concerne également des compositions pharmaceutiques et des procédés de traitement d'infections bactériennes au moyen des composés de formule (i).
MA32219A 2007-03-13 2009-09-11 Macrolides a base d'erythromycine MA31252B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89447507P 2007-03-13 2007-03-13
US2337008P 2008-01-24 2008-01-24
PCT/IB2008/000715 WO2008110918A2 (fr) 2007-03-13 2008-03-04 Macrolides

Publications (1)

Publication Number Publication Date
MA31252B1 true MA31252B1 (fr) 2010-03-01

Family

ID=39760163

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32219A MA31252B1 (fr) 2007-03-13 2009-09-11 Macrolides a base d'erythromycine

Country Status (28)

Country Link
US (1) US20080293646A1 (fr)
EP (1) EP2125851B1 (fr)
JP (1) JP4468487B1 (fr)
KR (1) KR20090110381A (fr)
CN (1) CN101631795A (fr)
AP (1) AP2009004985A0 (fr)
AR (1) AR065724A1 (fr)
AT (1) ATE471943T1 (fr)
AU (1) AU2008224633A1 (fr)
BR (1) BRPI0809002A2 (fr)
CA (1) CA2680527A1 (fr)
CL (1) CL2008000695A1 (fr)
CR (1) CR10998A (fr)
CU (1) CU20090155A7 (fr)
DE (1) DE602008001611D1 (fr)
DO (1) DOP2009000214A (fr)
EA (1) EA200901059A1 (fr)
EC (1) ECSP099627A (fr)
IL (1) IL200613A0 (fr)
MA (1) MA31252B1 (fr)
MX (1) MX2009009074A (fr)
PA (1) PA8772401A1 (fr)
PE (1) PE20090106A1 (fr)
SV (1) SV2009003368A (fr)
TN (1) TN2009000374A1 (fr)
TW (1) TW200848061A (fr)
UY (1) UY30957A1 (fr)
WO (1) WO2008110918A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2822953T5 (en) * 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
JP6437523B2 (ja) 2013-04-04 2018-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ マクロライドならびにそれらの調製および使用の方法
CN106998685A (zh) * 2014-10-08 2017-08-01 哈佛大学的校长及成员们 14‑元酮内酯及其制备和使用方法
EP3273969A4 (fr) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides à sucres modifiés de type désosamine et utilisations de ceux-ci
CN105924451B (zh) * 2016-04-27 2017-12-15 国家海洋局第三海洋研究所 具有抗茶叶致病真菌活性的大环内酯化合物及制备与用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA85937C2 (uk) * 2004-12-21 2009-03-10 Пфайзер Продактс Інк. Макроліди

Also Published As

Publication number Publication date
ATE471943T1 (de) 2010-07-15
CA2680527A1 (fr) 2008-09-18
WO2008110918A3 (fr) 2009-01-29
MX2009009074A (es) 2009-09-28
AR065724A1 (es) 2009-06-24
KR20090110381A (ko) 2009-10-21
CN101631795A (zh) 2010-01-20
EA200901059A1 (ru) 2010-02-26
AU2008224633A1 (en) 2008-09-18
DOP2009000214A (es) 2009-10-31
US20080293646A1 (en) 2008-11-27
DE602008001611D1 (en) 2010-08-05
TW200848061A (en) 2008-12-16
ECSP099627A (es) 2009-10-30
EP2125851A2 (fr) 2009-12-02
AP2009004985A0 (en) 2009-10-31
TN2009000374A1 (fr) 2010-12-31
IL200613A0 (en) 2010-05-17
SV2009003368A (es) 2009-11-09
BRPI0809002A2 (pt) 2014-11-11
CL2008000695A1 (es) 2008-09-22
WO2008110918A2 (fr) 2008-09-18
UY30957A1 (es) 2008-10-31
EP2125851B1 (fr) 2010-06-23
JP4468487B1 (ja) 2010-05-26
CR10998A (es) 2009-09-11
JP2010521448A (ja) 2010-06-24
PA8772401A1 (es) 2008-11-19
CU20090155A7 (es) 2011-04-26
PE20090106A1 (es) 2009-02-08

Similar Documents

Publication Publication Date Title
MA32615B1 (fr) Inhibiteurs de cmet
MA33642B1 (fr) Composés chimiques
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA32941B1 (fr) Composes organiques
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2009003821A (es) Compuestos de n-aril pirazol para usarse contra la diabetes.
MA33428B1 (fr) Agonistes du gpr119
MA31151B1 (fr) Inhibiteurs de mapk/erk kinase
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA32509B1 (fr) Composes organiques
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA33492B1 (fr) Inhibiteurs de bace
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak